Jennifer Lachey - Jul 15, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jul 15, 2022
Transactions value $
-$1,367,210
Form type
4
Date filed
7/19/2022, 04:40 PM
Previous filing
Jul 15, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $13.8K +46K +48.41% $0.30* 141K Jul 15, 2022 Direct
transaction KROS Common Stock Sale -$1.38M -46K -32.62% $30.00 95.1K Jul 15, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -46K -84.02% $0.00 8.76K Jul 15, 2022 Common Stock 46K $0.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.